AQST

Over the past six months, Aquestive Therapeutics experienced several stock-impacting events. On August 10, 2026, the company announced positive topline human factors and pharmacokinetic study results for Anaphylm Sublingual Film. Aquestive resubmitted its New Drug Application (NDA) for Anaphylm to the FDA on September 17, 2026. The Board of Directors was strengthened with the appointment of Richard Daly on September 29, 2026. Financially, for the second quarter of 2026, revenue increased by 38% year-over-year to $13.8 million, and the non-GAAP adjusted EBITDA loss improved. For the first quarter of 2026, revenue increased by 66% year-over-year, the net loss improved, and the company secured a new $150 million debt facility. As of October 2, 2026, the stock price was $4.55 per share, reflecting a 23.79% decline from October 6, 2025, a 21.87% decrease over the last 12 months, and a 13.17% decrease in the past month as of September 26, 2026. Additionally, a legal probe concerning alleged false claims about Anaphylm was announced in August 2026.